Pneumonia in the neutropenic cancer patient

Current Opinion in Pulmonary Medicine
Scott E Evans, David E Ost

Abstract

Pneumonia is the leading cause of death among neutropenic cancer patients, particularly those with acute leukaemia. Even with empiric therapy, case fatality rates of neutropenic pneumonias remain unacceptably high. However, recent advances in the management of neutropenic pneumonia offer hope for improved outcomes in the cancer setting. This review summarizes recent literature regarding the clinical presentation, microbiologic trends, diagnostic advances and therapeutic recommendations for cancer-related neutropenic pneumonia. Although neutropenic patients acquire pathogens both in community and nosocomial settings, patients' obligate healthcare exposures result in the frequent identification of multidrug-resistant bacterial organisms on conventional culture-based assessment of respiratory secretions. Modern molecular techniques, including expanded use of galactomannan testing, have further facilitated identification of fungal pathogens, allowing for aggressive interventions that appear to improve patient outcomes. Multiple interested societies have issued updated guidelines for antibiotic therapy of suspected neutropenic pneumonia. The benefit of antibiotic medications may be further enhanced by agents that promote host respon...Continue Reading

References

May 1, 1976·Medicine·H Y ChangE J Freireich
Feb 1, 1983·The American Journal of Medicine·J W KuglerM J Gilchrist
Jan 1, 1995·Respiration; International Review of Thoracic Diseases·M von EiffJ van de Loo
Jan 1, 1995·Cancer Treatment and Research·E WhimbeyG P Bodey
Jan 31, 1998·Bone Marrow Transplantation·P WhiteC B Miller
Apr 8, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Q NguyenE Whimbey
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J P SouzaS W Crawford
Sep 15, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettM J Fine
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Jul 31, 2001·Bone Marrow Transplantation·S KonoplevE Whimbey
Aug 30, 2001·Critical Care Clinics·A Safdar, D Armstrong
Nov 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Feb 28, 2002·Thorax·D G Peckham
Mar 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Mar 13, 2002·Lancet·Oscar Marchetti, Thierry Calandra
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Sep 28, 2002·Medicine·Harrys A TorresDimitrios P Kontoyiannis
Oct 16, 2002·American Journal of Respiratory and Critical Care Medicine·Ali A El-SolhJoan Davies
Dec 12, 2002·Chest·Jordi RelloUNKNOWN VAP Outcomes Scientific Advisory Group
Jan 7, 2003·Infectious Disease Clinics of North America·Kieren A MarrDavid Denning
Apr 15, 2003·Leukemia & Lymphoma·Giorgina SpecchiaVincenzo Liso
Jul 10, 2003·The Journal of Infection·F RoblotB Becq-Giraudon
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D YadegaryniaK Rolston
Oct 30, 2003·Cancer·Shahid AhmedKanti R Rai
Nov 14, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN Infectious Diseases Society of America
Dec 20, 2003·Lancet·Thomas M File
Feb 26, 2004·The European Respiratory Journal·R Bals, P S Hiemstra
Jun 11, 2004·The New England Journal of Medicine·Charles F Thomas, Andrew H Limper
Aug 11, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·G R De La RosaA Safdar

❮ Previous
Next ❯

Citations

Jun 19, 2016·Blood·Miguel M Leiva-JuárezScott E Evans
May 1, 2019·AJR. American Journal of Roentgenology·Richard ThomasMark M Hammer
Dec 4, 2019·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Barbara EbersoleNausheen Jamal
May 13, 2020·Antimicrobial Agents and Chemotherapy·Lukas PageSamuel Samnick
Oct 28, 2019·The Korean Journal of Internal Medicine·Sung Min JungWon Young Kim
Sep 16, 2017·Leukemia & Lymphoma·Victor Mulanovich, Dimitrios P Kontoyiannis
Jul 16, 2016·Respirology : Official Journal of the Asian Pacific Society of Respirology·Carlota GudiolJordi Carratalà
May 3, 2020·BMC Pulmonary Medicine·Jung Won HeoHye Seon Kang
Mar 19, 2015·Current Opinion in Pulmonary Medicine·Alimuddin Zumla, Michael S Niederman
Dec 31, 2020·Proceedings of the National Academy of Sciences of the United States of America·Megumi InomataJohn M Leong
Oct 12, 2016·Microbiology Spectrum·Karen C Carroll, La'tonzia L Adams
Nov 2, 2021·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Jordan A LangMalak Itani

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar
biopsies
PCR

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

New Horizons : an Official Publication of the Society of Critical Care Medicine
K V Leeper
Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America
P S CarlisleP H Wiernik
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation
Pınar Zeyneloğlu
Clinics in Chest Medicine
G B Toews
© 2021 Meta ULC. All rights reserved